Stocks Health care RAPP
NASDAQ · Health careRapport Therapeutics, Inc. (RAPP)
It posted a net loss of $150.5M. In fiscal 2025 capital spending exceeded operating cash flow by $88.1M. At September 30, 2026 it held $74.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Rapport Therapeutics, Inc.
- Net worth
- Rapport Therapeutics, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $391.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $87.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rapport Therapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Rapport Therapeutics, Inc. does
Rapport Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RAPP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$111.5M | -$2.86 | -$88.1M |
| 2024 | n/a | -$78.3M | -$3.78 | -$67.2M |
| 2024 | n/a | -$34.8M | -$23.10 | -$28.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Rapport Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- October 30, 2026
- October 29, 2026Form 305B2 filing 305B2
- October 20, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
- August 5, 2026
Insider trades
What the people running Rapport Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $22M and sold $4.5M worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Third Rock Ventures V, L.P.Director, 10% owner | Received as pay | 238,095 | $5M |
| October 30, 2026 | Third Rock Ventures V, L.P.Director, 10% owner | Received as payindirect | 1,190,476 | $25M |
| October 28, 2026 | Healy JamesDirector | Boughtindirect | 952,380 | $20M |
| October 28, 2026 | Healy JamesDirector | Boughtindirect | 6,395 | $134.3K |
| October 28, 2026 | Healy JamesDirector | Boughtindirect | 3,772 | $79.2K |
| October 28, 2026 | Healy JamesDirector | Boughtindirect | 6,933 | $145.6K |
| October 23, 2026 | Sanchez RamiroDirector | Bought | 3,600 | $98.5K |
| October 22, 2026 | Maraganore JohnDirector | Boughtindirect | 8,239 | $217.3K |
Who owns RAPP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Third Rock Ventures V, L.P.13G, passive with 5 related filers | 13.1% | August 14, 2026 |
| (S) ARCH Venture Fund XII, L.P.13G, passive with 6 related filers | 10.2% | November 14, 2024 |
| Capital International Investors13G, passive | 6.1% | August 12, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 5.56% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 161 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 7,172,894 | +3,955 |
| Trv GP V, LLC | 6,280,525 | -854,708 |
| ARCH Venture Management, LLC | 3,728,738 | 0 |
| Capital International Investors | 2,921,958 | -176,015 |
| Goldman Sachs Group Inc | 2,910,449 | -31,802 |
| BlackRock, Inc. | 2,699,786 | +193,831 |
| Cormorant Asset Management, LP | 2,657,521 | -300,000 |
| Sofinnova Investments, Inc. | 1,904,408 | 0 |
| Johnson & Johnson | 1,784,517 | 0 |
| Polar Capital Holdings Plc | 1,608,514 | -33,947 |
| Baker Bros. Advisors LP | 1,547,090 | 0 |
| Vanguard Capital Management LLC | 1,346,512 | +21,430 |
| Trv GP VI, LLC | 969,218 | 0 |
| State Street Corp | 818,712 | +59,160 |
| Geode Capital Management, LLC | 793,453 | +71,831 |
| Perceptive Advisors LLC | 773,342 | +99,419 |
| Vestal Point Capital, LP | 730,000 | -706,229 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 644,082 | -274,784 |
| Siren, L.L.C. | 641,469 | 0 |
| Capital World Investors | 551,657 | +15,050 |
Insiders
12 insiders reported holding 10,026,056 shares in total, about $261.4M at the last price.
| Holder | Shares |
|---|---|
| Third Rock Ventures V, L.P.Director, 10% owner | 8,678,3142,159,694 held indirectly |
| Ceesay AbrahamChief Executive Officer, Director | 470,76420,729 held indirectly |
| Bredt DavidChief Scientific Officer | 393,075 |
| Yeleswaram KrishnaswamyChief Development Officer | 195,862 |
| Gault CherylChief Operating Officer | 139,914 |
| Paul Steven MDirector | 77,38077,380 held indirectly |
| Healy JamesDirector | 25,26725,267 held indirectly |
| Ignelzi Troy A.Chief Financial Officer | 15,500 |
| Young Wendy B.Director | 13,289 |
| Maraganore JohnDirector | 9,4119,411 held indirectly |
Questions about RAPP
What does Rapport Therapeutics, Inc. do?
Rapport Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RAPP. Its shares trade on NASDAQ under the ticker RAPP.
What is Rapport Therapeutics, Inc.'s net worth?
Rapport Therapeutics, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $391.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rapport Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $150.5M.
When did Rapport Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Rapport Therapeutics, Inc.'s next earnings report?
Rapport Therapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RAPP with
Follow RAPP
Get an email when Rapport Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rapport Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.